71 research outputs found
Medical treatment of early stage and rare histological variants of epithelial ovarian cancer
Epithelial ovarian cancer is often considered a single pathological entity, but increasing evidence suggests that it is rather a group of different
neoplasms, each with unique pathological characteristics, molecular features, and clinical behaviours. This heterogeneity accounts for the
different sensitivity to antineoplastic drugs and makes the treatment of ovarian tumours a challenge.
For early-stage disease, as well as for heavily pre-treated patients with recurrent ovarian cancer, the benefit of chemotherapy remains
uncertain.
Clear-cell, mucinous, low-grade serous, and endometrioid carcinomas show different molecular characteristics, which require different
therapeutic approaches. In the era of personalised cancer medicine, understanding the pathogenesis and the genetic background of each
subtype of epithelial ovarian tumour may lead to a tailored therapy, maximising the benefits of specific treatments and possibly reducing
the side effects. Furthermore, personal factors, such as the patient’s performance status, should be taken into account in the management
of ovarian cancer, with the aim of safeguarding the patients’ quality of life
Retrospective study of histopathological and prognostic characteristics of primary fallopian tube carcinomas: twenty-year experience (SOCRATE)
Inactivated human platelet lysate is a new method to censure safer GMP-compliant MSC production.
A neuronal network of mitochondrial dynamics regulates metastasis.
The role of mitochondria in cancer is controversial. Using a genome-wide shRNA screen, we now show that tumours reprogram a network of mitochondrial dynamics operative in neurons, including syntaphilin (SNPH), kinesin KIF5B and GTPase Miro1/2 to localize mitochondria to the cortical cytoskeleton and power the membrane machinery of cell movements. When expressed in tumours, SNPH inhibits the speed and distance travelled by individual mitochondria, suppresses organelle dynamics, and blocks chemotaxis and metastasis, in vivo. Tumour progression in humans is associated with downregulation or loss of SNPH, which correlates with shortened patient survival, increased mitochondrial trafficking to the cortical cytoskeleton, greater membrane dynamics and heightened cell invasion. Therefore, a SNPH network regulates metastatic competence and may provide a therapeutic target in cancer
506 Oral metronomic cyclophosphamide in recurrent ovarian cancer: a single centre experience
n/
Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications
- …